By Kevin E.
Noonan --
On July 19th,
Myriad Genetics amended its complaint against Ambry Genetics to include claims
to its patents relating to colon cancer predictive genetic diagnostic testing (amended complaint). For those keeping score, the specific claims
Myriad alleges are infringed include the following: claim 6 of U.S.
Patent No. 5,709,999; claims 6, 16 and 17 of U.S.
Patent No. 5,747,282; claims 7, 8, 12, 23, and 26 of U.S.
Patent No. 5,753,441; claims 29 and 30 of U.S. Patent No.
5,837,492; claim 4 of U.S. Patent No. 6,033,857; claims 2, 3 and 4 of U.S. Patent
No. 5,654,155; claims 2, 3, 4, 5, 6, and 7 of U.S.
Patent No. 5,750,400; claims 32 and 33 of U.S. Patent No.
6,051,379; claim 5 of U.S. Patent No. 6,951,721; claims 3, 4, 5, 6, 7, 8, 11, 14,
17, 18, 19 of U.S. Patent No. 7,250,497; claims 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17 and 18 of U.S. Patent No. 7,470,510; claims 10, 11, 15, 16, 17 and 19 of
U.S. Patent No. 7,622,258; claims 2, 8 and 16 of U.S. Patent
No. 7,838,237; claims 2, 3, 5, 9, 10 and 12 of
U.S. Patent No. 7,670,776; and claims 2 and 7 of U.S. Patent
No. 7,563,571.
Comments